Suppr超能文献

抗丙型肝炎病毒 3a 基因型病毒样颗粒的单克隆抗体可抑制细胞培养系统中的病毒进入。

Monoclonal antibodies against Hepatitis C genotype 3a virus like particle inhibit virus entry in cell culture system.

机构信息

Department of Biochemistry, Indian Institute of Science, Bangalore, India.

出版信息

PLoS One. 2013;8(1):e53619. doi: 10.1371/journal.pone.0053619. Epub 2013 Jan 15.

Abstract

The envelope protein (E1-E2) of Hepatitis C virus (HCV) is a major component of the viral structure. The glycosylated envelope protein is considered to be important for initiation of infection by binding to cellular receptor(s) and also known as one of the major antigenic targets to host immune response. The present study was aimed at identifying mouse monoclonal antibodies which inhibit binding of virus like particles of HCV to target cells. The first step in this direction was to generate recombinant HCV-like particles (HCV-LPs) specific for genotypes 3a of HCV (prevalent in India) using the genes encoding core, E1 and E2 envelop proteins in a baculovirus expression system. The purified HCV-LPs were characterized by ELISA and electron microscopy and were used to generate monoclonal antibodies (mAbs) in mice. Two monoclonal antibodies (E8G9 and H1H10) specific for the E2 region of envelope protein of HCV genotype 3a, were found to reduce the virus binding to Huh7 cells. However, the mAbs generated against HCV genotype 1b (D2H3, G2C7, E1B11) were not so effective. More importantly, mAb E8G9 showed significant inhibition of the virus entry in HCV JFH1 cell culture system. Finally, the epitopic regions on E2 protein which bind to the mAbs have also been identified. Results suggest a new therapeutic strategy and provide the proof of concept that mAb against HCV-LP could be effective in preventing virus entry into liver cells to block HCV replication.

摘要

丙型肝炎病毒(HCV)的包膜蛋白(E1-E2)是病毒结构的主要组成部分。糖基化包膜蛋白被认为对于通过与细胞受体结合来启动感染很重要,并且也是宿主免疫反应的主要抗原靶标之一。本研究旨在鉴定抑制丙型肝炎病毒样颗粒(HCV-LP)与靶细胞结合的小鼠单克隆抗体。朝着这个方向的第一步是使用编码核心、E1 和 E2 包膜蛋白的基因在杆状病毒表达系统中产生针对 HCV 基因型 3a(在印度流行)的重组 HCV-LP。通过 ELISA 和电子显微镜对纯化的 HCV-LP 进行了表征,并在小鼠中生成了单克隆抗体(mAb)。针对 HCV 基因型 3a 包膜蛋白 E2 区的两种单克隆抗体(E8G9 和 H1H10)被发现可减少病毒与 Huh7 细胞的结合。然而,针对 HCV 基因型 1b(D2H3、G2C7、E1B11)产生的 mAb 则没有那么有效。更重要的是,mAb E8G9 显示出对 HCV JFH1 细胞培养系统中病毒进入的显著抑制作用。最后,还鉴定了与 mAb 结合的 E2 蛋白上的表位区域。结果表明了一种新的治疗策略,并提供了概念验证,即针对 HCV-LP 的 mAb 可能有效预防病毒进入肝细胞以阻止 HCV 复制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/72cd/3546081/85b14c6b98bd/pone.0053619.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验